Tenecteplase: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Tenecteplase}} | {{Tenecteplase}} | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
{{SB}} TNKASE<sup>®</sup> | {{SB}} TNKASE<sup>®</sup> | ||
| Line 10: | Line 8: | ||
'''Tenecteplase (TNK)''' is an [[enzyme]] used as a [[thrombolytic drug]]. | '''Tenecteplase (TNK)''' is an [[enzyme]] used as a [[thrombolytic drug]]. | ||
Tenecteplase is a [[tissue plasminogen activator]] (tPA) produced by recombinant DNA technology using an established mammalian cell line ( | Tenecteplase is a [[tissue plasminogen activator]] (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain. | ||
Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA. | Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA. | ||
| Line 19: | Line 17: | ||
'''| [[Tenecteplase indications and usage|Indications and Usage]]''' | '''| [[Tenecteplase indications and usage|Indications and Usage]]''' | ||
'''| [[Tenecteplase dosage and administration|Dosage and Administration]]''' | '''| [[Tenecteplase dosage and administration|Dosage and Administration]]''' | ||
'''| [[Tenecteplase contraindications|Contraindications]]''' | '''| [[Tenecteplase contraindications|Contraindications]]''' | ||
'''| [[Tenecteplase warnings and precautions|Warnings and Precautions]]''' | '''| [[Tenecteplase warnings and precautions|Warnings and Precautions]]''' | ||
| Line 25: | Line 22: | ||
'''| [[Tenecteplase drug interactions|Drug Interactions]]''' | '''| [[Tenecteplase drug interactions|Drug Interactions]]''' | ||
'''| [[Tenecteplase use in specific populations|Use in Specific Populations]]''' | '''| [[Tenecteplase use in specific populations|Use in Specific Populations]]''' | ||
'''| [[Tenecteplase description|Description]]''' | '''| [[Tenecteplase description|Description]]''' | ||
'''| [[Tenecteplase clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Tenecteplase clinical pharmacology|Clinical Pharmacology]]''' | ||
| Line 31: | Line 27: | ||
'''| [[Tenecteplase clinical studies|Clinical Studies]]''' | '''| [[Tenecteplase clinical studies|Clinical Studies]]''' | ||
'''| [[Tenecteplase how supplied storage and handling|How Supplied/Storage and Handling]]''' | '''| [[Tenecteplase how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Tenecteplase labels and packages|Labels and Packages]]''' | '''| [[Tenecteplase labels and packages|Labels and Packages]]''' | ||
Revision as of 22:24, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Synonyms / Brand Names: TNKASE®
Overview
Tenecteplase (TNK) is an enzyme used as a thrombolytic drug.
Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.
Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA.
FDA Package Insert
| Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages